Deltex Medical Regulatory News (DEMG)

19 Feb 2007 09:30

Deltex Medical Group PLC19 February 2007 Deltex Medical Group plc SupraQ(TM) monitor used to haemodynamically optimise a critically ill patient 19 February 2007 Deltex Medical Group plc ('Deltex Medical' or the 'Company'),the UK's leading haemodynamic monitoring company, announces the first case studyof the non-invasive SupraQ monitor being used to guide successful interventionin a critically ill patient. A man in his 50s was admitted as an emergency to the intensive care unit at theMedway Maritime NHS Hospital in Kent. He was suffering from both acute liverfailure and acute kidney failure and his system's blood clotting responses wereseverely compromised. The entirely non-invasive SupraQ was used instead of a combination of invasivecentral venous and peripheral arterial catheters. The SupraQ allowed doctors tohaemodynamically optimise the patient more quickly, more safely and moreaccurately than would have been possible with traditional invasive pressuremonitoring. Failure to successfully fluid resuscitate such patients isassociated with significantly increased risk of death. The full case study, which has been approved for distribution by the cliniciansresponsible for the patient, is available at www.deltexmedical.com/press_releases.php. Deltex Medical's chief executive, Andy Hill, commented: "The doctors at the Medway have been working extensively on the clinicalvalidation of the SupraQ for nearly a year. It is highly encouraging that theywere sufficiently confident of the SupraQ's abilities to use it to guidetreatment for such a sick patient. The SupraQ is expected to expandsignificantly the Company's unique ability to provide doctors with informationwhich allows them to respond quickly and accurately to changes in a patient'shaemodynamic status". For further information, please contact:- Deltex Medical Group plc 01243 774 837Nigel Keen, Chairman njk@deltexmedical.comAndy Hill, Chief Executive ahill@deltexmedical.comEwan Phillips, Finance Director eap@deltexmedical.com Gavin Anderson & Company 0207 554 1400Deborah Walter dwalter@gavinanderson.co.ukRobert Speed rspeed@gavinanderson.co.uk Charles Stanley Securities 020 7149 6457Russell Cook russell.cook@csysecurities.com Notes for Editors Deltex Medical manufactures and markets the CardioQ monitor, which usesdisposable ultra-sound probes inserted into the oesophagus to determine theamount of blood being pumped around the body - 'circulating blood volume'.Reduced circulating blood volume is known as hypovolaemia, which leads toinsufficient oxygen being delivered to the organs. This causes medicalcomplications including peripheral and major organ failure which can lead todeath. Hypovolaemia, which is akin to severe dehydration, affects virtuallyevery patient having surgery because of the combined effects of pre-operativestarvation, the impact of the anaesthetic agents and trauma from the surgeryitself. Using fluids and drugs, guided by the CardioQ, to optimise the amount ofcirculating blood significantly reduces post-operative complications allowingpatients to make a faster, more complete recovery and return home earlier. The CardioQ incorporates the Company's proprietary software and a smalldiameter, easy-to-use, minimally invasive, disposable oesophageal probe that isused for transmitting and receiving an ultra-sound signal. By using thistechnology, the CardioQ provides clinicians with the ability to haemodynamicallyoptimise critically ill patients and those undergoing routine moderate to majorsurgery through the controlled administration of fluid and drugs. Haemodynamicoptimisation has been scientifically proven to improve the speed and quality ofpatient recovery and reduce hospital stay. There are already over 1,250 CardioQs currently in use in hospitals worldwideand distribution arrangements are in place in over 30 countries. In addition,there are currently more than 90 clinical publications on the use of the CardioQwhich have repeatedly:- • Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works • Proved that the CardioQ works in a wide range of surgical procedures • Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients. The SupraQ is an entirely non-invasive device which uses an ultrasound probeheld at the base of the patient's neck to track the flow of blood in the aorta;it presents the same data as the CardioQ in a similar format and is used fortaking snapshots or monitoring over short periods. This information is provided by RNS The company news service from the London Stock Exchange